Medicover AB
OTC:MCVEF

Watchlist Manager
Medicover AB Logo
Medicover AB
OTC:MCVEF
Watchlist
Price: 27.25 USD Market Closed
Market Cap: $4.1B

Medicover AB
Investor Relations

Medicover AB, founded in 1995, is a prominent healthcare and diagnostic service provider, chiefly operating across Europe and India. The company, based out of Sweden, has carved a niche by offering a broad range of healthcare services, focusing on accessible and premium quality care. Medicover’s structure is multifaceted—comprising two main divisions: Healthcare Services and Diagnostic Services. Their healthcare division administers preventative and primary care services through outpatient clinics, as well as specialist hospital care, emphasizing a holistic approach to patient care. Meanwhile, the Diagnostic Services division performs a vital role, supplying an extensive array of laboratory and imaging services. This dual-pronged business model ensures a steady stream of revenue, bolstering Medicover’s position in the competitive healthcare landscape.

The way Medicover makes money is intricately tied to its wide-reaching network and comprehensive service offerings. Revenues are primarily derived from the fees for healthcare and diagnostic services provided directly to patients and through contracts with insurance companies and corporate clients, who seek Medicover’s expertise in employee health management. In navigating the healthcare sector, Medicover leverages its robust technological infrastructure to optimize service delivery and operational efficiency, ensuring patient satisfaction while maintaining cost-effectiveness. By continuously expanding its geographical footprint and diversifying its service portfolio, Medicover is adept at adapting to evolving market demands, thus securing its long-term financial sustainability and reinforcing its commitment to delivering value-driven healthcare solutions.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2025
Call Date
Apr 29, 2025
AI Summary
Q1 2025

Record Results: Medicover delivered its best quarterly report since listing, with strong top-line growth and significant margin expansion across most business units.

Margin Expansion: EBITDA margin increased by 1.6 percentage points and EBIT margin by 2.4 percentage points, showing clear operational leverage.

India Weakness: The Indian business had a disappointing quarter due to weak consumer sentiment and halted medical tourism, but management expects a return to strong double-digit growth in April.

Diagnostic Strength: Diagnostics division saw robust organic growth and margin improvement despite pricing pressures in Germany’s public sector; private pay in Germany is growing rapidly.

Financial Targets Achieved: On an annualized basis, Medicover has already met or exceeded its ambitious 2025 year-end financial targets with three quarters to spare.

Accretive M&A: Two recent acquisitions—SYNLAB assets and a fitness operator in Poland—are expected to be highly accretive, adding about EUR 80 million in annualized revenue.

Cash Flow & Leverage: Strong cash flow continued, and leverage improved to 3x, with management expecting a temporary rise in Q2 due to acquisitions before returning below 3x by year-end.

Key Financials
Organic Revenue Growth
More than 14%
EBITDA Margin
15%
EBITDA
EUR 86.5 million
Adjusted EBITDA
EUR 90.6 million
Adjusted EBITDA Margin
15.7%
Adjusted EBITDA after Lease (EBITDAaL)
EUR 60.4 million
EBIT
EUR 36 million
EBIT Margin
6.2%
EPS
Above EUR 0.13
Healthcare Services Revenue
EUR 403 million
Diagnostics Services Revenue
EUR 182 million
Net Operating Cash
EUR 87.5 million
Free Cash Flow
EUR 44.2 million
Return on Invested Capital (ROIC)
8.3%
Leverage
3x
CapEx
EUR 28 million (Q1)
Revenue (annualized run rate)
Around EUR 2.3 billion
Other Earnings Calls

Management

Mr. Fredrik Rågmark
CEO & Director
No Bio Available
Mr. Anand Patel
Chief Financial Officer
No Bio Available
Mr. Jaroslaw Urbanczyk
Chief Information Officer
No Bio Available
Hanna Bjellquist
Head of Investor Relations
No Bio Available
Ms. Jenny Brandt
General Legal Counsel
No Bio Available
Dr. Andrew Vallance-Owen FRCS Ed, MBA
Chief Marketing Officer
No Bio Available
Ms. Kamila Skorupinski
Group Chief People Officer
No Bio Available
Mr. John Paul Stubbington
Chief Operating Officer of Healthcare Services
No Bio Available
Mr. Staffan Ternstrom
Chief Operating Officer for Diagnostic Services
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Riddargatan 12 A 3Tr
Contacts
+468446461764646.0
www.medicover.com